Xingfeng Bao

Xingfeng Bao

Company: H3biomedicine

Job title: Senior Director, Immuno-Oncology


Xingfeng Bao is a Sr. Director at H3biomedicine Inc, an Eisai Oncology company in Cambridge MA, where he heads the Immuno-Oncology research responsible for initiating and advancing cancer immunotherapy programs through discovery into early clinical development. He has led several drug discovery projects at all stages of discovery and translational research with two compounds currently in clinical development. He received his doctorate in 2002 and completed his postdoctoral training in Tumor Microenvironment Biology and Immunobiology before he joined Eisai in 2011.  


Live Q&A 10:20 am

Read more

day: Online Conference

Intravesical Delivery of a Pan-Genotypically Active STING Agonist to Treat Non-Muscle Invasive Bladder Cancer (NMIBC) 9:20 am

• Discovery of a pan-genotypic active STING agonist • Demonstrate potent anti-tumor activity in orthotopic NMIBC models via intravesical administration • First clinical study of STING agonist in NMIBC patientsRead more

day: Online Conference

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.